Journal
NEUROLOGY
Volume 71, Issue 24, Pages S3-S7Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31818f3d6f
Keywords
-
Categories
Ask authors/readers for more resources
Multiple sclerosis (MS) involves ongoing accumulating CNS damage. Precisely which environmental factors trigger onset and progression of the disease are not known. However, clinical trials indicate benefits from early use of disease-modifying therapies (DMTs). All the completed clinically isolated syndrome trials (CHAMPS, ETOMS, BENEFIT, PRECISE) reported significant suppression of subsequent relapse and MRI lesion formation from use of DMT at the first relapse. This article reviews data on early treatment. Such an approach requires the ability to recognize clinically isolated syndrome features that indicate a diagnosis of MS. NEUROLOGY 2008; 71 (Suppl 3): S3-S7.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available